US FDA Panel Takes On Neurological Device Classification
While the panelists backed FDA recommendations for most devices discussed, they said two might need to be placed in class III so the agency can gather more information.
You may also be interested in...
Health care industry groups expressed support after the high court found that Texas and 17 other Republican-led states lacked standing to file suit because they hadn’t shown the act had directly harmed them.
Becton Dickinson claims Beckman Coulter has been knowingly violating several patents since at least 2015.
US President Joe Biden’s proposed budget for fiscal 2022 allocates $133.7bn for HHS, a 23% increase for the department from fiscal 2021; the administration is also asking for $6.5bn for the FDA, an 8% increase from the agency’s current budget.